+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics Manufacturing Market Size, Share & Trends Analysis Report by Mode of Manufacturing (Contract, in-House), Modality, Disease Indication, and Region with Growth Forecasts, 2025-2033- Product Image
Biologics Manufacturing Market Size, Share & Trends Analysis Report by Mode of Manufacturing (Contract, in-House), Modality, Disease Indication, and Region with Growth Forecasts, 2025-2033- Product Image
New

Biologics Manufacturing Market Size, Share & Trends Analysis Report by Mode of Manufacturing (Contract, in-House), Modality, Disease Indication, and Region with Growth Forecasts, 2025-2033

  • PDF Icon

    Report

  • 120 Pages
  • September 2025
  • Region: Global
  • Grand View Research
  • ID: 6176676
REQUEST CUSTOMIZATION
Description Jump to:
The global biologics manufacturing market size was estimated at USD 40.05 Billion in 2025 and is projected to reach USD 140.62 billion by 2033, growing at a CAGR of 17.0% from 2025 to 2033. This growth is primarily driven by increasing demand for biopharmaceuticals, expansion of biologics production capacities, and advancements in cell and gene therapy manufacturing technologies.

Rising burden of chronic disease

One of the main factors expanding the global biologics manufacturing industry is the rising incidence of chronic illnesses such as diabetes, cancer, autoimmune diseases, and cardiovascular conditions. Biologic therapies from living organisms provide targeted and efficient treatment options for these complex conditions, as conventional treatments frequently prove insufficient. The need for novel biologic medications has increased due to the growing number of patients needing long-term, specialized care, which stimulates producers to increase their production capacity and invest in cutting-edge technologies.

Furthermore, access to high-quality biologic therapies is becoming a top priority for healthcare systems worldwide due to the growing burden of chronic diseases. To enhance patient outcomes and lower the long-term treatment expenses related to managing chronic illnesses, governments and private healthcare providers are increasingly supporting the development and commercialization of biologics. Over the years, the market and regulatory emphasis on biologics production is anticipated to support steady expansion in manufacturing capacity and technological breakthroughs.

Growing Demand for Novel and Targeted Therapies

The rising need for innovative and focused treatments propels the biologics manufacturing market. Targeted biologics, including monoclonal antibodies, antibody-drug conjugates, and cell and gene therapies, differ from conventional medications in that they specifically target the molecular causes of illnesses. These treatments are very appealing for diseases such as cancer, autoimmune disorders, and rare genetic diseases because of their precision, which increases treatment efficacy and reduces side effects. Pharmaceutical and biotechnology companies are making significant investments in research pipelines to launch new targeted biologics.

Regulatory bodies in important markets concurrently establish favorable pathways for their approval to support the adoption of breakthrough biologics in clinical practice. Targeted therapy success has also increased industry competition, forcing producers to increase production capacity, embrace cutting-edge bioprocessing technologies, and form strategic alliances. As businesses work to satisfy the growing demand for novel, patient-specific treatments worldwide, these advancements are greatly accelerating the growth of the biologics manufacturing sector.

Global Biologics Manufacturing Market Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, the analyst has segmented the global biologics manufacturing market on the basis of mode of manufacturing, modality, disease indication, and region.

Mode of Manufacturing Outlook (Revenue, USD Million, 2021-2033)

  • Contract Manufacturing
  • In-house manufacturing

Modality Outlook (Revenue, USD Million, 2021-2033)

  • Monoclonal Antibodies (mAbs)
  • Biosimilar & Recombinant Proteins
  • Vaccines (recombinant/mRNA/Viral)
  • Cell & Gene Therapies
  • RNA-based Therapeutics
  • Others

Disease Indication Outlook (Revenue, USD Million, 2021-2033)

  • Oncology
  • Autoimmune Disorders
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disorders
  • Other Disease Indications

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segmental and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Mode
1.2.2. Modality
1.2.3. Disease Indication
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Impact Analysis
3.3.1.1. Rising burden of chronic disease
3.3.1.2. Growing Demand for Novel and Targeted Therapies
3.3.2. Market Restraint Impact Analysis
3.3.2.1. High Manufacturing Costs and Capital Intensity
3.3.2.2. Complex Regulatory and Quality Compliance
3.4. Business Environment Analysis
3.4.1. PESTLE Analysis
3.4.2. PORTER’S Five Forces Analysis
Chapter 4. Mode Business Analysis
4.1. Mode Segment Dashboard
4.2. Global Biologics Manufacturing Market Mode, Movement Analysis
4.3. Global Biologics Manufacturing Market Size & Trend Analysis, by Mode, 2021 to 2033 (USD Million)
4.4. Contract Manufacturing
4.4.1. Global contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
4.5. In-house manufacturing
4.5.1. Global in-house manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Chapter 5. Modality Business Analysis
5.1. Modality Segment Dashboard
5.2. Global Biologics Manufacturing Market Modality, Movement Analysis
5.3. Global Biologics Manufacturing Market Size & Trend Analysis, by Modality, 2021 to 2033 (USD Million)
5.4. Monoclonal Antibodies (mAbs)
5.4.1. Global monoclonal antibodies (mAbs) market estimates and forecasts, 2021-2033 (USD Million)
5.5. Biosimilar & Recombinant Proteins
5.5.1. Global biosimilar & recombinant proteins market estimates and forecasts, 2021-2033 (USD Million)
5.6. Vaccines (recombinant/mRNA/Viral)
5.6.1. Global vaccines (recombinant/mRNA/Viral) market estimates and forecasts, 2021-2033 (USD Million)
5.7. Cell & Gene Therapies
5.7.1. Global cell & gene therapies market estimates and forecasts, 2021-2033 (USD Million)
5.8. RNA-based Therapeutics
5.8.1. Global RNA-based therapeutics market estimates and forecasts, 2021-2033 (USD Million)
5.9. Others
5.9.1. Global others market estimates and forecasts, 2021-2033 (USD Million)
Chapter 6. Disease Indication Business Analysis
6.1. Disease Indication Segment Dashboard
6.2. Global Biologics Manufacturing Market Disease Indication, Movement Analysis
6.3. Global Biologics Manufacturing Market Size & Trend Analysis, by Disease Indication, 2021 to 2033 (USD Million)
6.4. Oncology
6.4.1. Global Oncology market estimates and forecasts, 2021-2033 (USD Million)
6.5. Autoimmune Disorders
6.5.1. Global autoimmune disorders market estimates and forecasts, 2021-2033 (USD Million)
6.6. Infectious Diseases
6.6.1. Global infectious diseases market estimates and forecasts, 2021-2033 (USD Million)
6.7. Neurological Disorders
6.7.1. Global neurological disorders market estimates and forecasts, 2021-2033 (USD Million)
6.8. Cardiovascular Disorders
6.8.1. Global cardiovascular disorders market estimates and forecasts, 2021-2033 (USD Million)
6.9. Others Disease Indications
6.9.1. Global other disease indications market estimates and forecasts, 2021-2033 (USD Million)
Chapter 7. Biologics Manufacturing Market: Regional Estimates and Trend Analysis, by Product, Mode, & Disease Indication,
7.1. Regional Dashboard
7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
7.3. North America
7.3.1. North America biologics manufacturing market, 2021-2033 (USD Million)
7.3.2. U.S.
7.3.2.1. Key Country Dynamics
7.3.2.2. Target Disease Prevalence
7.3.2.3. Competitive Scenario
7.3.2.4. Regulatory Framework
7.3.2.5. U.S. Biologics manufacturing market, 2021-2033 (USD Million)
7.3.3. Canada
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Canada biologics manufacturing market, 2021-2033 (USD Million)
7.3.4. Mexico
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Mexico biologics manufacturing market, 2021-2033 (USD Million)
7.4. Europe
7.4.1. Europe biologics manufacturing market, 2021-2033 (USD Million)
7.4.2. UK
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Competitive Scenario
7.4.2.4. Regulatory Framework
7.4.2.5. UK biologics manufacturing market, 2021-2033 (USD Million)
7.4.3. Germany
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Germany biologics manufacturing market, 2021-2033 (USD Million)
7.4.4. France
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. France biologics manufacturing market, 2021-2033 (USD Million)
7.4.5. Italy
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Italy biologics manufacturing market, 2021-2033 (USD Million)
7.4.6. Spain
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Spain biologics manufacturing market, 2021-2033 (USD Million)
7.4.7. Denmark
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Denmark biologics manufacturing market, 2021-2033 (USD Million)
7.4.8. Sweden
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. Sweden biologics manufacturing market, 2021-2033 (USD Million)
7.4.9. Norway
7.4.9.1. Key Country Dynamics
7.4.9.2. Target Disease Prevalence
7.4.9.3. Competitive Scenario
7.4.9.4. Regulatory Framework
7.4.9.5. Norway biologics manufacturing market, 2021-2033 (USD Million)
7.5. Asia-Pacific
7.5.1. Asia-Pacific biologics manufacturing market, 2021-2033 (USD Million)
7.5.2. Japan
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Competitive Scenario
7.5.2.4. Regulatory Framework
7.5.2.5. Japan biologics manufacturing market, 2021-2033 (USD Million)
7.5.3. China
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. China biologics manufacturing market, 2021-2033 (USD Million)
7.5.4. India
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. India biologics manufacturing market, 2021-2033 (USD Million)
7.5.5. Singapore
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Competitive Scenario
7.5.5.4. Regulatory Framework
7.5.5.5. Singapore biologics manufacturing market, 2021-2033 (USD Million)
7.5.6. Australia
7.5.6.1. Key Country Dynamics
7.5.6.2. Target Disease Prevalence
7.5.6.3. Competitive Scenario
7.5.6.4. Regulatory Framework
7.5.6.5. Australia biologics manufacturing market, 2021-2033 (USD Million)
7.5.7. Thailand
7.5.7.1. Key Country Dynamics
7.5.7.2. Target Disease Prevalence
7.5.7.3. Competitive Scenario
7.5.7.4. Regulatory Framework
7.5.7.5. Thailand biologics manufacturing market, 2021-2033 (USD Million)
7.5.8. South Korea
7.5.8.1. Key Country Dynamics
7.5.8.2. Target Disease Prevalence
7.5.8.3. Competitive Scenario
7.5.8.4. Regulatory Framework
7.5.8.5. South Korea biologics manufacturing market, 2021-2033 (USD Million)
7.6. Latin America
7.6.1. Latin America biologics manufacturing market, 2021-2033 (USD Million)
7.6.2. Brazil
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Competitive Scenario
7.6.2.4. Regulatory Framework
7.6.2.5. Brazil biologics manufacturing market, 2021-2033 (USD Million)
7.6.3. Argentina
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Argentina biologics manufacturing market, 2021-2033 (USD Million)
7.7. MEA
7.7.1. MEA biologics manufacturing market, 2021-2033 (USD Million)
7.7.2. South Africa
7.7.2.1. Key Country Dynamics
7.7.2.2. Target Disease Prevalence
7.7.2.3. Competitive Scenario
7.7.2.4. Regulatory Framework
7.7.2.5. South Africa biologics manufacturing market, 2021-2033 (USD Million)
7.7.3. Saudi Arabia
7.7.3.1. Key Country Dynamics
7.7.3.2. Target Disease Prevalence
7.7.3.3. Competitive Scenario
7.7.3.4. Regulatory Framework
7.7.3.5. Saudi Arabia biologics manufacturing market, 2021-2033 (USD Million)
7.7.4. UAE
7.7.4.1. Key Country Dynamics
7.7.4.2. Target Disease Prevalence
7.7.4.3. Competitive Scenario
7.7.4.4. Regulatory Framework
7.7.4.5. UAE biologics manufacturing market, 2021-2033 (USD Million)
7.7.5. Kuwait
7.7.5.1. Key Country Dynamics
7.7.5.2. Target Disease Prevalence
7.7.5.3. Competitive Scenario
7.7.5.4. Regulatory Framework
7.7.5.5. Kuwait biologics manufacturing market, 2021-2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2024
8.4. Company Profiles/Listing
8.4.1. Novartis AG
8.4.1.1. Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Pfizer Inc
8.4.2.1. Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Amgen Inc
8.4.3.1. Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Novo Nordisk A/S
8.4.4.1. Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. AbbVie Inc.
8.4.5.1. Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Johnson & Johnson (Johnson & Johnson Services, Inc.)
8.4.6.1. Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Bristol-Myers Squibb Company
8.4.7.1. Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Eli Lilly and Company
8.4.8.1. Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. F. Hoffmann La-Roche Ltd.
8.4.9.1. Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Wuxi Biologics
8.4.10.1. Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
8.4.11. FUJIFILM Holdings Corporation (FUJIFILM Diosynth Biotechnologies)
8.4.11.1. Overview
8.4.11.2. Financial Performance
8.4.11.3. Product Benchmarking
8.4.11.4. Strategic Initiatives
8.4.12. Boehringer Ingelheim International GmbH
8.4.12.1. Overview
8.4.12.2. Financial Performance
8.4.12.3. Product Benchmarking
8.4.12.4. Strategic Initiatives
8.4.13. Lonza
8.4.13.1. Overview
8.4.13.2. Financial Performance
8.4.13.3. Product Benchmarking
8.4.13.4. Strategic Initiatives
8.4.14. Samsung Biologics
8.4.14.1. Overview
8.4.14.2. Financial Performance
8.4.14.3. Product Benchmarking
8.4.14.4. Strategic Initiatives
List of Tables
Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. Global Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 4. Global Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 5. Global Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 6. Global Biologics Manufacturing Market, by Region, 2021-2033 (USD Million)
Table 7. North America Biologics Manufacturing Market, by Country, 2021-2033 (USD Million)
Table 8. North America Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 9. North America Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 10. North America Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 11. U.S. Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 12. U.S. Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 13. U.S. Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 14. U.S. Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 15. Canada Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 16. Canada Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 17. Canada Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 18. Canada Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 19. Mexico Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 20. Mexico Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 21. Mexico Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 22. Mexico Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 23. Europe Biologics Manufacturing Market, by Country, 2021-2033 (USD Million)
Table 24. Europe Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 25. Europe Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 26. Europe Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 27. Europe Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 28. Germany Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 29. Germany Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 30. Germany Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 31. Germany Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 32. UK Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 33. UK Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 34. UK Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 35. UK Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 36. France Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 37. France Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 38. France Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 39. France Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 40. Italy Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 41. Italy Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 42. Italy Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 43. Italy Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 44. Spain Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 45. Spain Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 46. Spain Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 47. Spain Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 48. Denmark Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 49. Denmark Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 50. Denmark Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 51. Denmark Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 52. Norway Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 53. Norway Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 54. Norway Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 55. Norway Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 56. Sweden Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 57. Sweden Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 58. Sweden Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 59. Sweden Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 60. Asia-Pacific Biologics Manufacturing Market, by Country, 2021-2033 (USD Million)
Table 61. Asia-Pacific Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 62. Asia-Pacific Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 63. Asia-Pacific Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 64. Asia-Pacific Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 65. China Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 66. China Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 67. China Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 68. China Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 69. Japan Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 70. Japan Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 71. Japan Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 72. Japan Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 73. India Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 74. India Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 75. India Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 76. India Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 77. South Korea Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 78. South Korea Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 79. South Korea Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 80. South Korea Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 81. Australia Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 82. Australia Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 83. Australia Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 84. Australia Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 85. Thailand Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 86. Thailand Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 87. Thailand Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 88. Thailand Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 89. Latin America Biologics Manufacturing Market, by Country, 2021-2033 (USD Million)
Table 90. Latin America Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 91. Latin America Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 92. Latin America Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 93. Latin America Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 94. Brazil Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 95. Brazil Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 96. Brazil Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 97. Brazil Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 98. Argentina Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 99. Argentina Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 100. Argentina Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 101. Argentina Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 102. Middle East and Africa Biologics Manufacturing Market, by Country, 2021-2033 (USD Million)
Table 103. Middle East and Africa Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 104. Middle East and Africa Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 105. Middle East and Africa Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 106. Middle East and Africa Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 107. South Africa Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 108. South Africa Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 109. South Africa Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 110. South Africa Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 111. Saudi Arabia Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 112. Saudi Arabia Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 113. Saudi Arabia Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 114. Saudi Arabia Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 115. UAE Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 116. UAE Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 117. UAE Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 118. UAE Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
Table 119. Kuwait Biologics Manufacturing Market, by Product, 2021-2033 (USD Million)
Table 120. Kuwait Biologics Manufacturing Market, by Mode, 2021-2033 (USD Million)
Table 121. Kuwait Biologics Manufacturing Market, by Modality, 2021-2033 (USD Million)
Table 122. Kuwait Biologics Manufacturing Market, by Disease Indication, 2021-2033 (USD Million)
List of Figures
Figure 1 Biologics manufacturing market segmentation
Figure 2 Data analysis models
Figure 3 Market formulation and validation
Figure 4 Data validation & publishing
Figure 5 Market research process
Figure 6 Information procurement
Figure 7 Primary research
Figure 8 Value-chain-based sizing & forecasting
Figure 9 QFD modelling for market share assessment
Figure 10 Market formulation & validation
Figure 11 Commodity flow analysis
Figure 12 Market outlook
Figure 13 Segment snapshot-1
Figure 14 Competitive landscape snapshot
Figure 15 Market trends & outlook
Figure 16 PESTEL analysis
Figure 17 Porter’s five forces analysis
Figure 18 Biologics manufacturing market: Mode outlook key takeaways
Figure 19 Biologics manufacturing market: Mode movement analysis
Figure 20 Contract manufacturing market, 2021-2033 (USD Million)
Figure 21 In-house manufacturing market, 2021-2033 (USD Million)
Figure 22 Biologics manufacturing market: Modality outlook key takeaways
Figure 23 Biologics manufacturing market: Modality movement analysis
Figure 24 Monoclonal antibodies (mAbs)market, 2021-2033 (USD Million)
Figure 25 Biosimilar & recombinant proteins market, 2021-2033 (USD Million)
Figure 26 Vaccines (recombinant/mRNA/Viral) market, 2021-2033 (USD Million)
Figure 27 Cell & gene therapies market, 2021-2033 (USD Million)
Figure 28 RNA-based therapeutics market, 2021-2033 (USD Million)
Figure 29 Others market, 2021-2033 (USD Million)
Figure 30 Biologics manufacturing market: Disease Indication outlook key takeaways
Figure 31 Biologics manufacturing market: Disease Indication movement analysis
Figure 32 Oncology market, 2021-2033 (USD Million)
Figure 33 Autoimmune disorders market, 2021-2033 (USD Million)
Figure 34 Infectious diseases market, 2021-2033 (USD Million)
Figure 35 Neurological disorders market, 2021-2033 (USD Million)
Figure 36 Cardiovascular disorders market, 2021-2033 (USD Million)
Figure 37 Other disease indications market, 2021-2033 (USD Million)
Figure 38 Regional marketplace outlook, 2024 & 2033 (USD Million)
Figure 39 Regional marketplace: Key takeaways
Figure 40 North America biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 41 Key country dynamics
Figure 42 U.S. biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 43 Key country dynamics
Figure 44 Canada biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 45 Key country dynamics
Figure 46 Mexico biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 47 Europe biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 48 Key country dynamics
Figure 49 Germany biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 50 Key country dynamics
Figure 51 UK biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 52 Key country dynamics
Figure 53 France biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 54 Key country dynamics
Figure 55 Italy biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 56 Key country dynamics
Figure 57 Spain biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 58 Key country dynamics
Figure 59 Denmark biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 60 Key country dynamics
Figure 61 Sweden biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 62 Key country dynamics
Figure 63 Norway biologics manufacturing market estimates and forecast, 2021-2033 (USD Million)
Figure 64 Asia-Pacific biologics manufacturing market estimates and forecast, 2021-2033, (USD Million)
Figure 65 Key country dynamics
Figure 66 Japan biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 67 Key country dynamics
Figure 68 China biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 69 Key country dynamics
Figure 70 India biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 71 Key country dynamics
Figure 72 South Korea biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 73 Key country dynamics
Figure 74 Australia biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 75 Key country dynamics
Figure 76 Thailand biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 77 Latin America biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 78 Key country dynamics
Figure 79 Brazil biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 80 Key country dynamics
Figure 81 Argentina biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 82 MEA biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 83 Key country dynamics
Figure 84 South Africa biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 85 Key country dynamics
Figure 86 Saudi Arabia biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 87 Key country dynamics
Figure 88 UAE biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 89 Key country dynamics
Figure 90 Kuwait biologics manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 91 Market position analysis
Figure 92 Market participant categorization
Figure 93 Strategic framework

Companies Mentioned

The leading players profiled in this Biologics Manufacturing market report include:
  • ovartis AG
  • fizer Inc
  • mgen Inc.
  • ovo Nordisk A/S
  • bbVie Inc.
  • ohnson & Johnson (Johnson & Johnson Services, Inc.)
  • ristol-Myers Squibb Company
  • li Lilly and Company
  • . Hoffmann La-Roche Ltd.
  • uxi Biologics
  • UJIFILM Holdings Corporation (FUJIFILM Diosynth Biotechnologies)
  • oehringer Ingelheim International GmbH
  • onza
  • amsung Biologics

Table Information

Report AttributeDetails
No. of Pages120
PublishedSeptember 2025
Forecast Period2025 - 2033
Estimated Market Value ( USD ) in 2025 $ 40.05 Billion
Forecasted Market Value ( USD ) by 2033 $ 140.62 Billion
Compound Annual Growth Rate17.0%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing, and Region, 2025-2033 - Product Image

Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing, and Region, 2025-2033

  • Report
  • 149 Pages
  • Global
From
U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report by Indication (Infectious Diseases, Metabolic & Genetic Diseases), by Application, by End Use, and Segment Forecasts, 2025-2033 - Product Image

U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report by Indication (Infectious Diseases, Metabolic & Genetic Diseases), by Application, by End Use, and Segment Forecasts, 2025-2033

  • Report
  • 120 Pages
  • United States
From
U.S. Biological Safety Testing Products And Services Market Size, Share & Trends Analysis Report By Product (Reagent & Kits, Services, Instruments), By Application (Stem Cell, Vaccines & Therapeutics, Gene Therapy), By Test Type, And Segment Forecasts, 2025 - 2033 - Product Image

U.S. Biological Safety Testing Products And Services Market Size, Share & Trends Analysis Report By Product (Reagent & Kits, Services, Instruments), By Application (Stem Cell, Vaccines & Therapeutics, Gene Therapy), By Test Type, And Segment Forecasts, 2025 - 2033

  • Report
  • 100 Pages
  • United States
From
Biological Safety Testing Market Size, Share, Trends, and Forecast by Product and Services, Test Type, Application, and Region, 2025-2033 - Product Image

Biological Safety Testing Market Size, Share, Trends, and Forecast by Product and Services, Test Type, Application, and Region, 2025-2033

  • Report
  • 148 Pages
  • Global
From
Bioprocess Validation Market Size, Share & Trends Analysis Report by Testing Type (Extractables & Leachables Testing, Bioprocess Residuals Testing), Stage (Process Design, Process Qualification), Mode, and Region with Growth Forecasts, 2025-2033 - Product Image

Bioprocess Validation Market Size, Share & Trends Analysis Report by Testing Type (Extractables & Leachables Testing, Bioprocess Residuals Testing), Stage (Process Design, Process Qualification), Mode, and Region with Growth Forecasts, 2025-2033

  • Report
  • 130 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.